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New Insights Into the Cardiometabolic Risks of Obesity*James A. de Lemos, MD, Ian J. Neeland, MDSEE PAGE 1221O besity has long been recognized as a riskfactor for the development of cardiovas-cular and metabolic disease including
hypertension, insulin resistance and diabetes, and
atherogenic dyslipidemia. In 1988, Reaven (1) noted
that these risk factors tend to cluster to form a syn-
drome deﬁned by a unifying pathophysiology leading
to multiplicative risk for atherosclerotic cardiovascu-
lar disease, which he called Syndrome X. Over a
decade later, the National Cholesterol Education Pro-
gram’s Adult Treatment Panel III report codiﬁed this
observation as the metabolic syndrome (MetS) and
highlighted abdominal obesity, speciﬁcally increased
waist circumference (WC), as a major component of
the syndrome (2). Although the health risks associ-
ated with obesity are clear, there is an emerging
appreciation that obesity per se, as deﬁned by simple
anthropometric measures such as WC or body mass
index (BMI), is neither necessary nor sufﬁcient to pro-
mote MetS and its consequences. Rather, it appears
that risk for cardiometabolic disease varies substan-
tially across different fat depots, and that an excess
of visceral adipose tissue (VAT) may be a primary
driver of the metabolic and cardiovascular complica-
tions of obesity. An increase in VAT is thought to
reﬂect the inability of the subcutaneous adipose tis-
sue (SAT) depot to sufﬁciently expand its clearance
and storage capacity in response to caloric excess,
leading to ectopic fat deposition in the viscera, liver,
heart, and skeletal muscle, with pro-inﬂammatory*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
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Although an increased WC identiﬁes individuals at
increased risk for atherosclerosis (3) and mortality
across different levels of BMI (4), WC is an imprecise
surrogate for the VAT phenotype. First, the correla-
tion between WC and VAT is highly variable among
different racial/ethnic groups, prompting the Inter-
national Diabetes Federation to deﬁne lower cutoffs
for abnormal WC in Asian populations (5). Second,
measurement of WC includes both VAT and SAT
compartments. These 2 depots are anatomically and
physiologically distinct, especially within the obese
population, and are differentially associated with
markers of cardiometabolic risk (6). VAT, but not SAT
or WC, has been shown to associate with incident
diabetes in obese adults (7) and has been linked to
increased risk for the development of cardiovascular
disease and cancer (8). Emerging from these data is
the concept that the burden of VAT, rather than
increased abdominal girth, is central to the patho-
genesis of cardiometabolic disease.Despite progress in characterizing obesity sub-
phenotypes based on visceral versus subcutaneous
adiposity, several key knowledge gaps remain.
Because few serial data are available evaluating
changes in VAT and SAT over time, it is unknown
whether the VAT depot is plastic and modiﬁable
independently of more general alterations in body
mass. Moreover, data are lacking on how longitudinal
changes in VAT and SAT relate to cardiometabolic
risk. In this issue of iJACC, Shah et al. (9) address
these critical knowledge gaps using data from
the Multi-Ethnic Study of Atherosclerosis. They
measured VAT and SAT area by computed tomogra-
phy (CT) in 1,511 participants and evaluated cross-
sectional associations between abdominal fat depots
and cardiometabolic risk markers across BMI cate-
gories. In these analyses, the authors conﬁrmed
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1237previous observations that VAT and SAT are only
weakly correlated and reﬂect divergent risk proﬁles.
Although VAT was associated with an adverse meta-
bolic phenotype characterized by atherogenic dysli-
pidemia, hyperglycemia, an altered adipocytokine
proﬁle, and increased coronary artery calciﬁcation,
SAT was associated with markers of general adiposity
and a lower coronary calcium score, consistent with
prior ﬁndings (6).
In the most novel component of their study,
the authors performed repeat CT assessment of
VAT and SAT on 253 participants without MetS at
baseline approximately 3 years after the initial
examination. They observed that changes in weight
were generally minor (median 0.3% [interquartile
range (IQR): 3% to 3%]) compared with considerably
larger changes in visceral (7% [IQR: 8% to 23%]) and
subcutaneous fat (6% [IQR: 6% to 19%]). Further-
more, the correlation between changes in VAT and
SAT was modest, suggesting that changes in one fat
depot may not parallel changes in the other. Both
baseline VAT and changes in VAT associated with
incident MetS in fully-adjusted models. In contrast,
changes in SAT did not independently associate with
MetS. Notably, neither waist circumference nor tri-
glyceride level associated with MetS in the fully-
adjusted model, suggesting that their role in the
MetS deﬁnition may be only as a crude reﬂection of
VAT burden. Overall, these ﬁndings suggest that an
increase in visceral adiposity impacts cardiometabolic
risk rather than weight gain in general and that, as the
authors succinctly state, “visceral adiposity is a BMI-
independent, dynamic, mechanistic hallmark of car-
diometabolic disease.”
The study by Shah et al. (9) does have important
limitations. The abdominal fat depot assessments
were performed post-hoc using CT images that were
not prospectively designed for fat quantiﬁcation. This
resulted in substantial missing imaging data requiring
imputation. Also, only 17% of participants were
included in the serial CT substudy, introducing issues
of generalizability and selection bias for themost novel
ﬁndings of the study. Most importantly, the selection
of MetS as the study endpoint limits the clinical im-
plications of the ﬁndings. The value of predicting or
reclassifying the hazard for this cluster of risk factors is
not as evident as for incident disease outcomes such as
diabetes or atherosclerotic cardiovascular disease.
Despite these limitations, this study provides impor-
tant new insights into the understanding of the car-
diometabolic risks of obesity.
The ﬁnding that relatively larger changes in
abdominal fat may occur with smaller changes in
weight are provocative and demonstrate thesubstantial “plasticity” of abdominal fat depots,
especially VAT. This also highlights the importance
of assessing changes in VAT in addition to weight,
as accounting for only the latter may overlook
biologically-relevant changes in adiposity. These
ﬁndings also prompt other questions about the
biology of abdominal fat. For example, what drives
this plasticity? Why do some individuals deposit
large amounts of ectopic fat at relatively low
BMI, whereas in others, the subcutaneous depot is
able to expand adequately and protect against
ectopic fat deposition? Are these determinants
solely genetic or can alterations in dietary and
physical activity behaviors impact fat distribution?
Would targeted reduction of VAT without affecting
SAT or muscle mass have a salutary effect on car-
diometabolic risk?
Although much remains to be learned, the ﬁnd-
ings from Shah et al. (9) and other recent studies
suggest a path forward. First, the scientiﬁc commu-
nity should recognize that BMI and WC in isolation
are not sufﬁciently comprehensive measures of
adiposity-related risk in the individual patient.
Abnormal fat distribution reﬂective of more perva-
sive adipose tissue dysfunction should emerge as a
complementary prevention and treatment target.
Second, simpler and less expensive ways to accu-
rately assess ectopic/visceral adiposity are sorely
needed to better characterize cardiometabolic risk,
as CT and magnetic resonance imaging measures
may not be practical for widespread use. Until
simpler measures are available, other mitigating
factors should be taken into account when assessing
adiposity-related cardiometabolic risk, including
race/ethnicity, behavioral barriers such as poor
physical activity and nutritional choices, and evi-
dence for metabolic dysfunction beyond the speciﬁc
MetS criteria such as the presence of fatty liver dis-
ease or sleep-disordered breathing. Third, the
focus on patient care should shift from the ambig-
uous, failure-prone, and potentially stigmatizing
recommendation of generalized weight loss to
more targeted interventions to prevent VAT gain
or support VAT loss. Clinical trials of lifestyle
interventions, pharmacologic agents, and bariatric
surgery should transition from an overly simplistic
focus on changes in body mass to also consider
approaches to reduce ectopic and dysfunctional
adiposity. These studies should embed serial
abdominal imaging in their protocols to delineate
which therapies are most effective in reducing the
burden of VAT and other ectopic depots. It may
ﬁnally be time to “separate the VAT from the fat,”
recognizing abnormal fat distribution as a key
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1238pathophysiologic driver of MetS. Clinical and inves-
tigative efforts should increasingly address the
epidemics of obesity, sedentary lifestyle, and nutri-
tional excess within a framework of ectopic/visceral
adiposity to reduce the burden of metabolic and
cardiovascular disease.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
James A. de Lemos, University of Texas Southwestern
Medical Center, 5323 Harry Hines Blvd, Mail Code
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